.css-1xsl8rf{width:100%;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;position:relative;overflow:hidden;background:var(--alert-bg);-webkit-padding-start:var(--chakra-space-4);padding-inline-start:var(--chakra-space-4);-webkit-padding-end:var(--chakra-space-4);padding-inline-end:var(--chakra-space-4);padding-top:var(--chakra-space-1);padding-bottom:var(--chakra-space-1);--alert-fg:var(--chakra-colors-orange-600);--alert-bg:var(--chakra-colors-orange-100);font-weight:var(--chakra-fontWeights-semibold);padding-left:var(--chakra-space-4);}.chakra-ui-dark .css-1xsl8rf:not([data-theme]),[data-theme=dark] .css-1xsl8rf:not([data-theme]),.css-1xsl8rf[data-theme=dark]{--alert-fg:var(--chakra-colors-orange-200);--alert-bg:rgba(251, 211, 141, 0.16);}@media screen and (min-width: 48em){.css-1xsl8rf{padding-left:var(--chakra-space-8);}}Bitte aktivieren Sie Javascript um alle Funktionen nutzen zu können und ihre Nutzererfahrung zu verbessern.

Andreas Straube

Redner

01.07.2023
10:00 – 10:30 25 Min. 5 Min.
Vortrag
Kopfschmerzen bei/nach Covid-19-Infektion und Impfung: Was ist gesichert

Vortrag

30.06.2023
19:45 – 19:50 5 Min. 0 Min.
Poster IND
P10
Fremanezumab Effectiveness and Tolerability in Clinical Routine: Interim Real-World-Data of the Observational FINESSE Study
Migräne
30.06.2023
19:50 – 19:55 5 Min. 0 Min.
Poster IND
P11
Early onset of Real-World Effectiveness of Fremanezumab in Patients with Migraine who switched from another mAb targeting the CGRP pathway (subgroup analysis from FINESSE)
Migräne

Weitere Beteiligungen

30.06.2023
19:25 – 19:30 5 Min. 0 Min.
Poster
P06
Kinetische Oszillationsstimulation zur präventiven Behandlung von chronischer Migräne
Migräne
30.06.2023
19:45 – 19:50 5 Min. 0 Min.
Poster IND
P10
Fremanezumab Effectiveness and Tolerability in Clinical Routine: Interim Real-World-Data of the Observational FINESSE Study
Migräne
30.06.2023
19:50 – 19:55 5 Min. 0 Min.
Poster IND
P11
Early onset of Real-World Effectiveness of Fremanezumab in Patients with Migraine who switched from another mAb targeting the CGRP pathway (subgroup analysis from FINESSE)
Migräne